Vaccines and Global Health: The Week in Review
15 October 2022 :: Issue 675
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
Milestones, Perspectives

SAGE October 2022 meeting highlights published
10 October 2022  WHO Departmental news

Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization – 3-6 October 2022
(Full report will be published in the Weekly Epidemiological Record on 16 December 2022, and only the wording of the full report should be considered as final)

Report from the department of Immunization, Vaccines, and Biologicals
- Immunization programmes globally face many challenges in an increasingly complex world that faces unprecedented pressures, including state-based conflict, massive population displacement, economic crisis, and the existential threat of climate change.
- Two years into the pandemic, disruptions to service delivery persist in countries across income levels with backsliding in coverage and an increase in the number of zero-dose children.
- The decline in vaccination coverage has led to large disruptive outbreaks of measles and circulating vaccine derived polio viruses mainly affecting low- and low-middle-income countries, while outbreaks of Monkeypox has newly affected high-income countries in the Americas and Europe. These competing priorities divert attention from other essential health services.
- While COVID-19 vaccination targets were not achieved, including among priority-use groups, lessons learned from the pandemic response can be leveraged to strengthen immunization programmes and deliver vaccine across the life-course.

Report from Gavi, the Vaccine Alliance
- The zero-dose agenda and supporting countries in recovering will remain a priority for the Alliance.
- The refresh of the Gavi strategy (Gavi 5.1) will reiterate the focus on the zero-dose agenda and the relaunch of human papilloma virus (HPV) vaccination, while also adding the objective for the potential of long-term support for COVID-19 vaccination and regional vaccine manufacturing.
- The Alliance will continue its support for polio eradication while leveraging lessons learned to support the zero-dose agenda.
- The Alliance is preparing to launch malaria vaccination in the Malaria Vaccine Implementation Plan (MVIP) countries initially, and plans to expand the use of Zaire ebolavirus vaccines held in a stockpile to prevent vaccines passing their expiry dates.
- The Alliance is closely monitoring the Monkeypox, and Sudan ebolavirus outbreaks and stands ready to engage with partners if required.

Progress with implementation of IA2030
- SAGE was presented with the 2022 technical progress report on the Immunization Agenda 2030 (IA2030), providing an overview of global immunization data for 2021, an update on the operationalisation of the strategy and proposed recommendations to address the short- and long-term challenges to achieving the IA2030 goals and targets.
SAGE was also presented with updates from each of the WHO regional offices on the status of implementation of IA2030, the challenges and lessons learned, and actions being taken to operationalize IA2030 in each region.

Several factors that impede the achievement of the IA2030 goals and targets cut across the regions and country income levels and include: inadequate and overstretched health workforce, exacerbated through the COVID-19 response; insecurity and population displacement; competing priorities and diversion of resources from routine service delivery; and inadequate financing.

Most regions have developed regional strategies in alignment with IA2030 and have developed or are in the process of finalizing operationalization frameworks and M&E processes and are taking urgent actions to mitigate the risk of further VPD outbreaks.

The Measles & Rubella Initiative (M&RI) will join the IA2030 partnership structure to promote alignment in efforts to use measles as a tracer to identify service delivery gaps and take coordinated measures to strengthen immunization systems.

**Monkeypox**

- SAGE was presented with the monkeypox vaccination strategy developed under the umbrella of the Strategic Preparedness, Readiness and Response Plan (SPRP) and with the results of a rapid review on the performance and safety of smallpox vaccines for the prevention of monkeypox in the current multi-country monkeypox outbreak.
- Based on the available, limited data, SAGE recommended primary preventive (pre-exposure) vaccination (PPV) for groups at high risk for exposure to monkeypox. The group at highest risk of exposure in the current outbreak is gay, bisexual, or other men who have sex with men (MSM) with multiple sexual partners. Others at risk include individuals with multiple casual sexual partners; sex workers; health workers at repeated risk of exposure; laboratory personnel working with orthopoxviruses; clinical laboratory and health care personnel performing diagnostic testing for monkeypox; and outbreak response staff. The level of risk of infection may be used for prioritization in case of limited vaccine supply.
- Post-exposure vaccination (PEPV) is recommended for close contacts of cases, ideally within 4 days of first exposure and up to 14 days in the absence of symptoms.
- For healthy adults, any of the three currently available vaccines is appropriate. For individuals for whom replicating or minimally replicating vaccines are contra-indicated, non-replicating vaccines should be used. Specific recommendations apply on vaccine choice for special populations.
- SAGE emphasized that research on monkeypox in previously affected countries has been neglected, and strongly recommended that evidence on the epidemiology and epi-zoonotic situation of monkeypox disease in previously affected countries and the relationship with animal vectors be generated. In addition, vaccine use need to be accompanied with research to assess safety and effectiveness of interventions.
- Updated interim recommendations on monkeypox vaccination will be published.

**Respiratory Syncytial Virus (RSV)**

- SAGE was presented with data on the burden of RSV disease, the product pipeline for long-acting monoclonal antibody (mAb) and on maternal vaccines for protection of young infants.
- The burden of acute lower respiratory tract infections (ALRTI) remains high with an estimated more than 100 000 deaths attributed to RSV in children under 5 years; 97% of deaths occur in low-income (LICs) and lower middle-income countries (LMICs) and 45% occur in infants < 6 months.
- Market authorization of a long-acting monoclonal antibody by a stringent regulatory authority (SRA) is imminent (Q4 2022); also, a maternal vaccine in phase 3 development is expected to have an interim efficacy readout by end of 2022 with possible licensure in 2023 by a SRA.
- The WHO RSV vaccine technical advisory group reviewed available evidence on the performance and mechanism of action of the long-acting monoclonal antibodies and maternal immunization and concluded that these products would likely work equally well in countries across income levels, despite the fact that high-income countries (HICs) accounted for the majority of subjects enrolled in the clinical trials.

- A pre-fusion F protein vaccine when administered to pregnant women showed 85% efficacy against medically attended RSV ALRTI and 91% against severe RSV ALRTI in infants in a phase 2b clinical trial; a phase 3 trial is underway with results from an interim analysis expected in mid-2023.

- SAGE noted the potential availability of effective preventive interventions to prevent severe RSV disease in a relatively short time frame and recommended to conduct a thorough review of the existing and emerging data, especially as relevant to LIC and LMIC populations where most deaths occur.

- The need for more data in LIC and LMIC to understand the full public health potential of these vaccines will require studies that should be initiated now, in collaboration with WHO.

Poliomyelitis

- SAGE expressed concern about renewed wild poliovirus 1 (WPV1) circulation in Pakistan; and about continuing detections of WPV1 in South-eastern Africa. Further, SAGE noted ongoing the transmission of vaccine-derived poliovirus type 2 (VDPV2), particularly in the African region and in Yemen, as well as detections in New York, London, and Jerusalem. SAGE stressed the need for increased efforts to improve routine coverage of polio vaccination.

- SAGE endorsed the option for the timely initial use of the inactivated poliovirus vaccine (IPV) to respond to outbreaks, in countries that use only IPV for routine childhood immunization. This option is recommended if the poliovirus transmission is confined to a well-defined population group or geographical area and with high levels of sanitation; preparation for a response with oral polio vaccines (OPVs) should begin in parallel should transmission continue following the response with IPV.

- SAGE provided guiding principles on selection of target age group in outbreak response campaigns. SAGE reiterated that the outbreak response campaigns should primarily target children less than 5 years, though wider age range response may be considered when there is evidence of immunity gaps in older age groups or low historical vaccination coverage rates.

- SAGE stressed the importance of improving routine immunization coverage and called on the polio eradication programme to take actions to ensure that zero dose children identified by the programme are included in routine immunization micro plans for all recommended pediatric vaccines. SAGE also recognized the importance of accelerated efforts to develop and authorize novel OPVs against type 1 and 3 virus.

- SAGE also recommended that all countries have outbreak response plans to be prepared for timely response against VDPV or WPV1 outbreak.

COVID-19 vaccines

- SAGE reviewed the safety and immunogenicity of the bivalent vaccines containing the mRNA of the original strain and of the Omicron sub lineages when given as a booster dose in adults, and the clinical trial results from a protein subunit vaccine manufactured by Biological E, BECOV-2 (Corbevax™).

Variant-containing COVID-19 vaccines

- Achieving high and equitable rates of primary series vaccination with ancestral strain vaccines remain the highest public health priority.
- Four variant-containing bivalent mRNA vaccines which either include BA.1 or BA. 4-5 in combination with the ancestral virus have been authorized for use as booster doses.
- SAGE reviewed and endorsed a good practice statement stating that currently available data are not sufficient to support the issuance of any preferential recommendation for bivalent variant-containing vaccine boosters over ancestral-virus-only boosters.
- Booster vaccination 4-6 months after the last dose provides improved protection against currently circulating SARS-CoV-2. Either the monovalent ancestral virus vaccines or bivalent variant-containing vaccines can be used as boosters. The bulk of the benefit is from the provision of a booster dose, irrespective of whether it is a monovalent or bivalent vaccine.

**Vaccine product specific recommendations: Biological E BECOV-2 vaccine (Corbevax™)**
- SAGE reviewed data on the Biological E BECOV-2 COVID-19 vaccine (Corbevax™) and will issue recommendations once the product is listed by WHO for emergency use (EUL).

**Briefing on the Sudan ebolavirus outbreak**
- SAGE was provided with an update of the ongoing outbreak of the Sudan ebolavirus vaccine in Uganda. The outbreak was declared on the 20th of September 2022 with the index case detected on the 11th of September 2022. As of October 6, there are 44 confirmed cases, 20 suspected cases and 10 deaths reported from 5 districts in Uganda.
- Vaccines against the Zaire ebolavirus do not offer cross-protection against the Sudan ebolavirus. There are 6 candidate vaccines under development against the Sudan ebolavirus, 3 of which have undergone phase 1 or 2 clinical trials.
- The opportunity of a vaccination response will be used to evaluate the efficacy of one of the candidate vaccines using a ring vaccination approach similar to that used for the Guinea trial with the Zaire ebolavirus vaccine, with the difference that only contacts will be offered vaccination to optimize the use of the limited doses of vaccine. The protocols are undergoing regulatory and ethics review.

:::}

**ISC and WHO sign new agreement furthering mutual scientific cooperation for global health and sustainable development**

14 October 2022, Geneva – The International Science Council (ISC) and the World Health Organization (WHO) have today signed a Memorandum of Understanding (MoU) to ensure mutual scientific cooperation aimed at promoting and achieving healthier lives and wellbeing for all.

The new agreement will facilitate and consolidate collaboration efforts between the two organizations considering their common goals relating to research, development and innovation in global health, and in the interest of better responding to and solving health issues of global concern. The agreement aims to enhance the contribution of science to global health and sustainable development, to facilitate mobilization of scientific expertise and to strengthen science-policy interfaces relevant to health...

With the ISC’s unique global membership representing both the natural and social sciences, and the WHO’s authority within the United Nations system to direct and coordinate, this new agreement will strengthen the contribution of the international scientific community to the advancement of health research, development and innovation. The MoU will also promote dialogues on how to tackle health issues of global relevance by bringing to bear integrated knowledge across all sciences.
To this end, both organizations have agreed to work together on:

▪ **Advancing global health research and sustainable development**, including in the areas of foresight, horizon scanning, knowledge sharing and shaping of the global research agenda.

▪ **Advancing evidence-informed decision-making** for health policy and programmes.

▪ **Strengthening trust in science** for better uptake of health advice through communicating public health guidelines, collaborating on the creation and use of digital content, and addressing mis- and dis-information.

While the WHO and the ISC have already collaborated recently on work related to the coronavirus pandemic, notably on the ISC’s policy report *Unprecedented & Unfinished: COVID-19 and Implications for National and Global Policy*, this new agreement now enables both organizations to focus on their shared strategic and operational priorities and to use their comparative strengths and advantages to maximize impact. Combining and connecting the scientific and policy expertise of both organizations will be key to ensuring evidence-based decision-making in the broad area of health and to strengthening trust in science at the global scale.

------

**Framework for the Involvement of Health Regulatory Authorities in the Management of Global Health Crises**

Crisis Management :: Standard Operating Procedure for Crisis Management

ICMRA October 13, 2022 :: 16 pages


Global health crises, including public health emergencies of international concern, are by nature unpredictable, multifaceted and involve multiple external stakeholders in addition to regulators. Hence, it is important to clarify the role of regulators and to open pathways for international engagement in a coordinated, aligned regulatory and policy response with a collaborative communication strategy.

This document presents the framework for the involvement of Regulatory Authorities (RAs) in the management of global health crises. The work was developed by the Crises Management Group of ICMRA, led by Anvisa (Brazilian Health Regulatory Agency - Brazil) and MHRA (Medicines and Healthcare Products Regulatory Agency - United Kingdom), who have been working together to identify opportunities and challenges that arise during the management of a global health crisis.

The Framework was previously published as the ICMRA Standard Operating Procedure (SOP) for Crisis Management, in 2019. The updated Framework provides experiences, learnings and real-life examples related to the COVID-19 pandemic. In the main body of the Framework, types of scenarios that Regulatory Authorities (RAs) may encounter during a public health scenario, the principles, roles, and responsibilities of the ICMRA Secretariat and members are described.

In 2022, the protocol was updated to provide experiences, learnings and real-life examples related to the COVID-19 pandemic. It describes types of scenarios that Regulatory Authorities may encounter during a public health crisis, the principles, roles, and responsibilities, as well as strategies for communication and international collaboration.
Members discuss extending MC12 TRIPS Decision to COVID-19 diagnostics and therapeutics

World Trade Organisation
13 October 2022

WTO members advanced discussions on whether to extend the TRIPS Decision adopted in June at the 12th WTO Ministerial Conference to COVID-19 diagnostics and therapeutics. At a meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) on 12-13 October, the chair of the Council, Ambassador Dr Lansana Gberie of Sierra Leone, urged delegations to submit text-based proposals indicating how they envisage an agreed outcome on this issue with a view to helping members reach a decision by the prescribed 17 December deadline.

At the 12th WTO Ministerial Conference (MC12), trade ministers adopted the Ministerial Decision on the TRIPS Agreement, which confirms the right of members over the next five years to override the exclusive effect of patents and provide greater scope to take direct action to diversify production of COVID-19 vaccines through clarifications of existing flexibilities and a targeted waiver.

The Decision also contains a commitment that, no later than six months from the date of its adoption (17 June), members will decide on its possible extension to cover the production and supply of COVID-19 diagnostics and therapeutics.

Ambassador Gberie invited delegations with concrete positions on what the TRIPS Council should decide to submit and circulate in writing text-based proposals (position papers, outlines, detailed drafts, or fully formulated decisions) so that these documents contribute to guiding the discussion.

The chair reported he had established a schedule of meetings aiming at helping members find convergence. Three additional rounds of informal discussion at the TRIPS Council are being convened on 2 November, 16 November and 6 December, with the possibility of calling members for another meeting on 15 December, two days before the deadline. In the meantime, this agenda item of the TRIPS Council will remain open in order to resume in formal mode before the 17 December deadline to potentially take a decision...

A total of 29 members took the floor on this issue to welcome the successful outcome at MC12 as proof that WTO members can bridge differences and collaborate to respond to the most urgent health challenges of our time. In the discussions, three different approaches emerged.

A group of developing and least-developed country (LDC) members who support an extension of the Decision to cover COVID-19 diagnostics and therapeutics favoured a blanket approach of the extension to therapeutics and diagnostics and stressed that the current COVID-19 IP waiver decision should be adopted “as is” without adding any further language or definition which would imply new negotiations.

These members emphasized that the pandemic is far from over and noted that equitable access to therapeutics and diagnostics is critical in helping detect new COVID-19 cases...
and variants. These delegations said that this extension is more urgent than ever, as many least developed countries (LDCs) lack access to life-saving drugs and testing therapeutics.

A group of developing and developed members expressed their readiness to advance the discussions but insisted on seeing evidence of where and how intellectual property (IP) constitutes a barrier to access to therapeutics and diagnostics before considering an extension. These members also reiterated the need for members to fully make use of all the flexibilities that already exist in the TRIPS Agreement (including compulsory licensing) before requesting new flexibilities...

PHEIC

Monkeypox
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/situations/monkeypox-oubreak-2022

No new digest content identified...latest report dated 5 October 2022

PHEIC

Coronavirus [COVID-19] - WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Weekly Epidemiological and Operational updates
Last update: 14 Oct 2022
Confirmed cases :: 620 878 405
Confirmed deaths :: 6 543 138
Vaccine doses administered: 12 723 216 322

Weekly epidemiological update on COVID-19 – 12 October 2022
Overview
Globally, the number of new weekly cases decreased by 10% during the week of 3 to 9 October 2022, as compared to the previous week, with over 2.8 million new cases reported. The number of new weekly deaths remained stable (-1%), as compared to the previous week, with about 9000 fatalities reported.
As of 9 October 2022, 618 million confirmed cases and 6.5 million deaths have been reported globally.
WHO Director-General’s opening remarks at the 13th meeting of the IHR Emergency Committee on COVID-19 pandemic – 13 October 2022

Professor Houssin, Members and Advisors of the Emergency Committee, dear colleagues and friends,

We have never been in a better position to end COVID-19 as a global health emergency. The number of weekly reported deaths is near the lowest since the pandemic began. And two-thirds of the world’s population is vaccinated, including 75% of health workers and older people.

But our work is not yet finished. There are still wide disparities in vaccination rates. While almost two-thirds of the world’s population has completed a primary course of vaccination, three-quarters of people in low-income countries are yet to receive a single dose.

Most countries no longer have measures in place to limit the spread of the virus; And most countries have reduced surveillance drastically, while testing and sequencing rates are also much lower. This is blinding us to the evolution of the virus and the impact of current and future variants.

Several countries in Europe are now reporting an increase in COVID-19 cases, hospitalizations and deaths. This is to be expected, as the weather cools in the northern hemisphere and people spend more time together inside. Given the current situation, we expect continued transmission of the virus, and we expect reported cases of COVID-19 to increase.

But even if cases increase, deaths don’t have to. We have the vaccines, therapeutics and know-how to save lives. As the pandemic evolves, so must the response.
WHO’s 2022 Strategic Preparedness, Readiness and Response Plan outlines the key measures that all countries need in place to reduce and control infections and save lives. We are concerned that most countries are not using all the tools at their disposal. It is important that countries maintain and further strengthen their surveillance, testing and sequencing capacities, so that they can quickly identify and trace the virus. At the moment, most countries are not doing this.

Countries also need to ensure access to diagnostics, antivirals and treatment for all, especially those most at-risk. But again, there are still unacceptable gaps in access, putting far too many at risk of severe disease and death.

My colleagues will provide technical updates on the current epidemiological situation, virus evolution, future scenarios, and the use of life saving tools. My thanks once again to you, Professor Houssin, for your leadership. And my thanks to each of the committee members and advisors for sharing your expertise, and for your dedication and commitment. As always, the International Health Regulations will guide your deliberations. I wish you a productive discussion, and I look forward to your recommendations. I thank you.

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 07 July 2022
[New additions; Full scale view available at title link above]

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 15 Oct 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

COVID-19 Global Targets and Progress Tracker - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

Duke – Launch and Scale Speedometer

The Race for Global COVID-19 Vaccine Equity

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research
COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out

15 Oct 2022 | COVAX (WHO, GAVI, CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 120M total confirmed cases; 2.3M total confirmed deaths

Global vaccines administered: 12.8B

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 370M
Other Delivered (Number of Doses): 390M
Total Delivered (Number of Doses): 750M
Total Administered (Number of Doses): 520M
Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/

https://data.covid19taskforce.com/data

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed 15 Oct 2022: https://data.covid19taskforce.com/data The global view below is complemented by country-specific dashboards here.
Our World in Data

**Coronavirus (COVID-19) Vaccinations** [Accessed 15 Oct 2022]

- 68.3% of the world population has received at least one dose of a COVID-19 vaccine.
- 12.83 billion doses have been administered globally, and 2.8 million are now administered each day.
- 23.3% of people in low-income countries have received at least one dose.

---

**U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

**HHS**

*News*

No new digest content identified.

**FDA**

*Press Announcements*


---

**Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

**European Medicines Agency**

*News & Press Releases*

*[News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022 (new)](https://www.ema.europa.eu)*

CHMP, Last updated: 14/10/2022
The CHMP recommended granting a marketing authorisation for Dengue Tetravalent Vaccine (Live, Attenuated) Takeda for the prevention of dengue virus serotypes 1, 2, 3 and 4 in people from four years of age. Dengue is a mosquito-borne tropical disease caused by the dengue virus, leading to mild flu-like symptoms in most people. However, a small number of patients develop severe disease, with potentially fatal bleeding and organ damage. The global estimated death rate is 20,000 to 25,000 per year, primarily in children. Dengue tetravalent vaccine prevents fever, severe disease and hospitalisation caused by any of the four serotypes of the dengue virus. This vaccine received an EMA recommendation under the EU Medicines for all (EU-M4All) programme, a mechanism that allows the CHMP to assess medicines that are intended for use in low- and middle-income countries outside of the European Union (EU). Simultaneously, the vaccine has also received a positive opinion for use in the EU, under the trade name Qdenga. See more information in the news announcement in the grid below...

**News: New vaccine to protect people in the EU and worldwide against dengue (new)**
CHMP, Last updated: 14/10/2022

**News: High-quality data to empower data-driven medicines regulation in the European Union (new)**
Last updated: 10/10/2022

-----

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en

**Latest Updates [Selected]**

**News**

Weekly COVID-19 country overview
Epidemiological update - 14 Oct 2022

**News**

Joint ECDC-WHO/Europe monkeypox surveillance bulletin
Epidemiological update - 12 Oct 2022

**News**

Monkeypox situation update, as of 11 October 2022
Epidemiological update - 12 Oct 2022

**News**

Ebola outbreak in Uganda under ECDC monitoring
News - 12 Oct 2022

**News**

Working together towards COVID-19 and seasonal influenza vaccinations for this winter
News - 12 Oct 2022

-----

European Commission
Joint Statement by Commissioner Stella Kyriakides, WHO Regional Director for Europe Dr Hans Henri P. Kluge and Director of the ECDC Dr Andrea Ammon: working together towards COVID-19 and seasonal influenza vaccinations for this winter

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment
Russia: Sputnik V – "the first registered COVID-19 vaccine”
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment
Ministry of Health and Family Welfare
https://www.mohfw.gov.in/
Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify any substantive, official announcements about China’s COVID response in general, or in Shanghai, Beijing or other China locations.]

PHEIC
Polio

Polio this week as of 05 Oct 2022 - GPEI
:: GPEI Pledging Moment, 18 October 2022, Berlin, Germany: GPEI leaders, donors, polio-affected countries and advocates will gather in Berlin next week at the World Health Summit for a global polio pledging moment, co-hosted by Germany’s Federal Ministry for Economic Cooperation and Development (BMZ).
:: To strengthen polio transition efforts and respond to changes in polio eradication and the broader global health landscape, WHO has developed a corporate management response to the mid-term evaluation of the implementation of the Strategic Action Plan on Polio Transition (2018-2023). Recognizing that eradication and transition efforts go hand-in-hand, the document lays out a clear roadmap to sustain polio knowledge, expertise and functions in order to strengthen national health systems, tailored to regional and country context. Find out more.
:: Scientific Declaration on Polio Eradication launched: this week, more than 2,800 leading scientists, physicians and global health experts from around the world launched the 2022 Scientific Declaration for Polio Eradication, highlighting the feasibility of eradication and urgently needed now.
Outcomes of SAGE meeting: the summary of the outcomes/recommendations from last week’s Strategic Advisory Group of Experts on immunization (SAGE) meeting, held in Geneva, Switzerland, on 3-6 October, are now available here. On polio eradication, SAGE had reviewed the latest global epidemiology and evaluated new outbreak response options, including for IPV-only using countries and expanded age groups. The full SAGE report will be published over the coming weeks in the Weekly Epidemiological Record (WER).

Pakistan polio infrastructure continues to support flood relief, while intensifying eradication efforts. “Rarely have I seen such commitment and dedication as I have seen in Pakistan,” commented Dr Hamid Jafari, Director for Polio Eradication, WHO Eastern Mediterranean.

EMRO commitments to polio eradication: Members of the Regional Subcommittee for Polio Eradication and Outbreaks in the Eastern Mediterranean reviewed recent progress during the 69th session of the EMRO Regional Committee. During the meeting Member States and partners reiterated their commitment to freeing current and future generations of children from polio and called for sustained efforts to end polio once and for all, including the pockets of wild poliovirus that linger in Afghanistan and Pakistan.

Summary of new polioviruses this week:
– DR Congo: four cVDPV2 cases and one cVDPV2 positive environmental sample
– Nigeria: three cVDPV2 cases

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
Afghanistan: Humanitarian Access Snapshot (September 2022)
Posted: 13 Oct 2022

Northern Ethiopia
No new digest content identified.

Somalia
No new digest content identified.

Ukraine
Situation Highlights 12 Oct 2022

WHO & Regional Offices [to 15 Oct 2022]
https://www.who.int/news
Selected News/Announcements/Statements
14 October 2022  Departmental news
Influenza in the northern hemisphere is back
14 October 2022  Departmental news
Influenza pandemic preparedness planning in the Islamic Republic of Iran

14 October 2022  Departmental news

Integrating SARS-CoV-2 and influenza surveillance in Timor-Leste

14 October 2022  Departmental news

Estimating seasonal influenza burden across the disease severity pyramid

14 October 2022  Departmental news

WHO conducts an open webinar to introduce the global guidance framework for the responsible use of the life sciences

14 October 2022  Departmental news

Bangladesh picks up influenza A(H3N2) outbreak despite COVID-19 challenges

13 October 2022  Departmental news

WHO convenes global experts to update guidance on national TB prevalence surveys

12 October 2022  Departmental news

WHO issues a new framework to strengthen collaborative action on TB and comorbidities

11 October 2022  Departmental news

WHO meeting discusses new strategies to tackle skin NTDs in West Africa

10 October 2022  Departmental news

SAGE October 2022 meeting highlights published

:::::::

WHO Director General Speeches  [selected]
https://www.who.int/director-general/speeches

Selected Speeches
14 October 2022
Speech
WHO Director-General's opening remarks at the MOU Signing Ceremony with International Science Council (ISC) – 14 October 2022

13 October 2022
Speech
WHO Director-General's opening remarks at the Member State Information Session on COVID-19 and other issues – 13 October 2022

13 October 2022
Speech
WHO Director-General's opening remarks at the 13th meeting of the IHR Emergency Committee on COVID-19 pandemic – 13 October 2022

12 October 2022
WHO Director-General's opening remarks at media briefing – 12 October 2022

12 October 2022
Speech
WHO Director-General's opening remarks at high-level emergency ministerial meeting on cross-border collaboration for preparedness and response to ebola virus disease - 12 October 2022

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region
:: African health ministers take steps to curb Ebola disease outbreak 12 October 2022
:: Sierra Leone targets cervical cancer mortality by vaccinating girls 11 October 2022

WHO Region of the Americas PAHO
:: Cholera’s resurgence in Haiti a reminder of how quickly diseases spread, PAHO Director says 12 Oct 2022
Parallel health emergencies put the region under pressure and highlight importance of resilient health systems. Washington D.C., 12 October 2022 (PAHO) – The Director of the Pan American Health Organization (PAHO), Dr. Carissa F. Etienne, said the recent cholera outbreak in Haiti, a steady increase in monkeypox cases, ongoing COVID-19...

WHO South-East Asia Region SEARO
No new digest content identified.

WHO European Region EURO
:: 14 October 2022  News release
Preparedness without borders: New emergency risk communication school and simulation bring training to life
:: 14 October 2022  Statement
Statement - The escalation of the humanitarian emergency requires an escalation of the humanitarian response
:: 14 October 2022  News release
New WHO Country Office in Cyprus agreed

WHO Western Pacific Region
:: Strengthening primary health care in the Western Pacific 11 October 2022

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.
13 October 2022 | Dengue - Pakistan

12 October 2022 | Cholera - Haiti

10 October 2022 | Dengue fever - Nepal

WHO Events
https://www.who.int/news-room/events/1
[Selected]
World Health Summit 2022
16 – 18 October 2022

Webinar: The role of vaccines in preventing AMR
18 October 2022: 10.00-11.30 (CET)

New WHO Publications
https://www.who.int/publications/i
Selected Titles
14 October 2022
Global programme to eliminate lymphatic filariasis: progress report, 2021

13 October 2022
Quality and safety practices for malaria rapid testing services

12 October 2022
Framework for collaborative action on tuberculosis and comorbidities

11 October 2022
Pandemic influenza preparedness framework: progress report, 1 January - 30 June 2022

10 October 2022
WHO Global Task Force on TB Impact Measurement – Report of a subgroup meeting on methods used by WHO...

CDC/ACIP [U.S.] [to 15 Oct 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases
CDC Expands Updated COVID-19 Vaccines to Include Children Ages 5 Through 11
October 12, 2022
**ACIP Meetings**

Next ACIP Meeting
October 19, 2022: 8:30am – 5:30pm ET
October 20, 2022: 8:30am – 4:00pm ET

These meetings are virtual. No registration is required to watch the webcasts.

[Agenda – Draft [2 pages]]
[Webcast Link]

---

**MMWR Weekly: Current Volume (71)**

October 14, 2022 / No. 41

[PDF of this issue]

- HIV Stigma and Health Care Discrimination Experienced by Hispanic or Latino Persons with HIV — United States, 2018–2020
- Adverse Childhood Experiences During the COVID-19 Pandemic and Associations with Poor Mental Health and Suicidal Behaviors Among High School Students — Adolescent Behaviors and Experiences Survey, United States, January–June 2021

---

**Coronavirus Disease 2019 (COVID-19)- CDC**

Approximately 15 announcements/reports/data summaries.

---

**Africa CDC**  [to 15 Oct 2022]
[http://www.africacdc.org/]

*News*

African Health Ministers Take Steps to Curb the Spread of the Ebola Disease Outbreak
12 October 2022

*Press Releases*

Strengthening Mortality Surveillance in Africa: Africa CDC launches continental framework document to support member states
12 October 2022

---

**China CDC**
[http://www.chinacdc.cn/en/]

National Health Commission of the People's Republic of China  [to 15 Oct 2022]
Oct 15: Daily briefing on novel coronavirus cases in China

On Oct 14, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 361 new cases of confirmed infections.

National Medical Products Administration — PRC  [to 15 Oct 2022]  
http://english.nmpa.gov.cn/  
Chinese mainland reports 249 new local confirmed COVID-19 cases  
2022-10-14  
The Chinese mainland on Thursday reported 249 locally transmitted confirmed COVID-19 cases, including 56 in Inner Mongolia and 53 in Guangdong, according to the National Health Commission's report Friday.

CCDC Weekly Reports: Current Volume (4)  
2022-10-14 / No. 41  
View PDF of this issue  
- Preplanned Studies: Predictors for Treatment Outcomes in Patients with Multi-drug Resistant Tuberculosis — China, 2018–2020  
- Vital Surveillances: Long-Term Trend Analysis of Major Human Helminth Infections — Guangdong Province, China, 1988–2021  
- Policy Notes: Consideration of Monkeypox Surveillance in China, 2022

Organization Announcements

Editor's Note:  
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group  [to 15 Oct 2022]  
https://alleninstitute.org/news-press/  
News  
No new digest content identified.

BMGF - Gates Foundation  [to 15 Oct 2022]  
https://www.gatesfoundation.org/ideas/media-center  
Press Releases and Statements  
No new digest content identified.
Bill & Melinda Gates Medical Research Institute [to 15 Oct 2022]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
News: Articles and Publications
No new digest content identified.

CARB-X [to 15 Oct 2022]
https://carb-x.org/
News
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 15 Oct 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of Vaccines and Global Health: The Week in Review are available here.
:: Informed Consent: A Monthly Review – October 2022 is now posted here
:: Genomic Medicine Governance, Ethics, Policy: A Quarterly Review - May 2022 is now posted here

CEPI – Coalition for Epidemic Preparedness Innovations [to 15 Oct 2022]
http://cepi.net/
Latest News
As CEPI ramps up vaccine research, a new study warns Lassa fever is set to expand its reach across Africa
   Climate change and other environmental factors could cause Lassa fever to spread. CEPI is the leading funder of research into vaccines against the potentially deadly virus.
12 Oct 2022

Rift Valley fever: What’s next for the climate-driven disease with epidemic potential?
A Q+A with CEPI Vaccine R&D Project Leader, Mike Whelan, discussing the characteristics of the disease and CEPI's new call with the European Union to advance Rift Valley fever vaccines.
10 Oct 2022

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 15 Oct 2022]
https://cioms.ch/
News; Publications
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 15 Oct 2022]
Duke Global Health Innovation Center  [to 15 Oct 2022]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP  [to 15 Oct 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center  [to 15 Oct 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative  [to 15 Oct 2022]
http://www.euvaccine.eu/
Latest News, Events
No new digest content identified

Evidence Aid  [to 15 Oct 2022]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
Selected Resources
Preventing COVID-19 transmissions among healthcare workers (research up to April 2020)
Added October 13, 2022

Fondation Merieux  [to 15 Oct 2022]
http://www.fondation-merieux.org/
News, Events
No new digest content identified

Gavi  [to 15 Oct 2022]
GHIT Fund  [to 15 Oct 2022]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified

Global Fund  [to 15 Oct 2022]
News & Stories
No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]  [to 15 Oct 2022]
https://www.gloid-r.org/news/
News
Countdown to GloPID-R General Assembly: October 19-20 in Berlin
October 12, 2022

Hilleman Laboratories  [to 15 Oct 2022]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified.

HHMI - Howard Hughes Medical Institute  [to 15 Oct 2022]
https://www.hhmi.org/news
Press Room
No new digest content identified.

Human Vaccines Project  [to 15 Oct 2022]
http://www.humanvaccinesproject.org/
News
Making Headlines
Oct 13, 2022
The Progress Network: What Could Go Right?

IAVI  [to 15 Oct 2022]
https://www.iavi.org/
Latest News
Russia-Ukraine international armed conflict: ICRC asks for immediate and unimpeded access to all prisoners of war

The Third Geneva Convention obliges parties to an international armed conflict to grant the International Committee of the Red Cross (ICRC) immediate access to all POWs, and the right to visit them wherever they are held.
14-10-2022 | News release

In these times of heightened international tension, shared humanitarian values must be the common ground for states to move forward

Statement of the International Committee of the Red Cross (ICRC), at the 77th session of the United Nations General Assembly, First Committee General Debate on all disarmament and international security agenda items — 12 October 2022.
13-10-2022 | Statement

Framework for the Involvement of Health Regulatory Authorities in the Management of Global Health Crises

[See Milestones above for detail]

Ebola in Uganda: Red Cross and community members fight the virus’s spread

Sri Lanka’s vulnerable forced to risk “a pathway to destitution”

Heatwaves account for some of the deadliest disasters and are intensifying, warn the IFRC and the UN humanitarian relief agency ahead of COP27
Institut Pasteur  [to 15 Oct 2022]
Press Documents
No new digest content identified.

IOM / International Organization for Migration  [to 15 Oct 2022]
News
12 Oct 2022
Three-Quarters of Refugees and Migrants from Venezuela Struggle to Access Basic Services in Latin America and the Caribbean

ISC / International Science Council  [to 15 Oct 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
Current
News  Press releases
ISC and WHO sign new agreement furthering mutual scientific cooperation for global health and sustainable development
14.10.2022
[See Milestones above for detail]

International Union of Immunological Societies (IUIS)
https://iuis.org/
News/Events [Selected]
No new digest content identified.

IVAC  [to 15 Oct 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

IVI  [to 15 Oct 2022]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security  [to 15 Oct 2022]
MSF/Médecins Sans Frontières  [to  15 Oct 2022]
http://www.msf.org/
Latest [Selected Announcements]
Syria
Cholera spreads across Syria putting vulnerable people at serious risk
Project Update 14 Oct 2022

Somalia
An alarming cycle of drought, malnutrition and disease in Baidoa
Project Update 12 Oct 2022

National Academy of Medicine - USA  [to  15 Oct 2022]
https://nam.edu/programs/
News [Selected]
No new digest content identified.

National Academy of Sciences - USA  [to  15 Oct 2022]
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS  [to  15 Oct 2022]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

NIH  [to  15 Oct 2022]
http://www.nih.gov/
News Releases
Monkeypox treatment trial begins in the Democratic Republic of the Congo
October 12, 2022 — NIH partnering with INRB to evaluate tecovirimat (TPOXX).

PATH  [to  15 Oct 2022]
https://www.path.org/media-center/
Press Releases
PATH board of directors welcomes Sylvana Q. Sinha
Seattle, October 10, 2022 - PATH's board of directors is thrilled to welcome Sylvana Q. Sinha as its newest member. Sinha brings extensive global strategic and operational expertise in international law,
business, development, and government relations. For more than 20 years, she has collaborated with
diverse players across sectors and industries in the Middle East, Africa, and South Asia to deliver
impactful governance and legal reforms as well as advocating for women’s rights, gender equality, and
social protection.

**Rockefeller Foundation** [to 15 Oct 2022]
https://www.rockefellerfoundation.org/
Selected Reports/Press Releases
No new digest content identified.

**Sabin Vaccine Institute** [to 15 Oct 2022]
https://www.sabin.org/press/
Latest News & Press Releases
No new digest content identified.

**UNAIDS** [to 15 Oct 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
11 October 2022
**Six cities and a Ukrainian community-led organization recognized at Fast-Track Cities 2022 Conference**

11 October 2022
**Sevilla Declaration on the centrality of affected communities in urban HIV responses unveiled at Fast-Track Cities 2022 conference**

10 October 2022
**Communities at the centre of an orchestrated emergency response to monkeypox in Peru**

10 October 2022
**Former UNAIDS Country Director, Michel de Groulard, remembered for championing communities**

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 15 Oct 2022]
News Releases
No new digest content identified.

**UNICEF** [to 15 Oct 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
No new digest content identified.
No new digest content identified.

**Unitaid** [to 15 Oct 2022]
https://unitaid.org/
Featured News
No new digest content identified.

**Vaccine Equity Cooperative [nee Initiative]** [to 15 Oct 2022]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 15 Oct 2022]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.

**Vaccine Confidence Project** [to 15 Oct 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 15 Oct 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

**Wellcome Trust** [to 15 Oct 2022]
https://wellcome.ac.uk/news
News. Opinion, Reports
Opinion
Author: Gordon Dougan
*From pandemics to prevention: our vision for Infectious Disease*
13 October 2022

**The Wistar Institute** [to 15 Oct 2022]
Press Releases
Oct. 12, 2022
*Wistar Scientists Identify Link Between Mitochondria and Pancreatic Cancer Risk*
Multi-gene expression signature in tumors correlates with aggressive disease and poor patient outcomes and could become genetic cancer biomarker.
**World Medical Association [WMA]** [to 15 Oct 2022]

**Press Releases**

**WMA General Assembly**
10.10.2022

Delegates from 57 national medical associations around the world attended the annual General Assembly of the WMA from 5 to 8 October. Among the issues discussed were:

**Ukraine**

Delegates reaffirmed their support for physician colleagues in Ukraine and condemned the Russian army’s bombing of Ukrainian civilians and hospitals, infringing medical neutrality in conflict zones. They called for an end to hostilities and urged all parties to ensure that access to medical care is guaranteed to all victims, civil or military, without distinction. They also called on the international community and governments to come to the aid of all those displaced by the conflict.

**Iran**

The meeting expressed its deep concern at reports of violence against protesters in Iran, where many people are reported to have died, many more are said to have been detained and medical vehicles have been abused by Iranian authorities to bring protesters to detention. Delegates urged the Iranian authorities to fully adhere to its human rights obligations, including the right to peaceful demonstration, to respect the autonomy of physicians and in particular their ethical duty to provide care to anyone on the basis of medical need alone, and to ensure that healthcare equipment and facilities are used for health care purposes only.

**Ethical Use of Social Media**

New guidelines were agreed, stating that physicians should avoid any inappropriate use of social media networks, such as frivolous, insensitive attitudes or light-hearted opinions on medical matters. Delegates urged national medical associations to produce guidelines to combat misinformation, disinformation, and the promotion of pseudoscience and pseudo-therapy, all of which could result in negative health outcomes for patients and communities.

**The Use of Telehealth**

The Assembly issued a warning to patients and physicians to be discerning in their use of digital
health and to be careful of the potential risks. It approved new guidelines for physicians, saying that the largely unregulated growth in the number and variety of digital health services could have patient safety and ethical implications. The guidelines make it clear that ‘face to face consultation should be the gold standard where a physical examination is required to establish a diagnosis, or where there is a wish on the part of the physician or patient to communicate in person’.

New President

Dr. Osahon Enabulele, former President of the Nigerian Medical Association, was installed as the 73rd President of the WMA for 2022-23.

Dr. Lujain Alqodmani, a leading public health doctor from Kuwait, was elected unopposed as President elect of the WMA. She is the first Arab to be elected President and will take up her post at the WMA’s General Assembly in Kigali, Rwanda in October 2023.

Dr. Tohru Kakuta (Japan) was elected unopposed as Vice-Chair of Council.

Dr. Jacques de Haller, President of the Swiss Association of General Practitioners and a former President of the Standing Committee of European Doctors, was elected Chair of the Associate Members.

Other Policies

Other policies adopted by the Assembly include guidance on discrimination against the elderly, physicians treating their relatives, assisted reproductive technologies, prison conditions and tuberculosis, and chronic diseases.

Policies adopted can be found on the WMA website: www.wma.net

Physician Leaders Demand Action to Prevent Workplace Violence

10.10.2022

Physician leaders across the world have strongly condemned a significant increase in violence against healthcare personnel and facilities, particularly during the Covid pandemic.

A statement adopted at the World Medical Association’s annual General Assembly in Berlin, says this violence in the health sector includes co-worker violence, aggressive behavior by patients or family members, and involves acts of malicious intent, both physical and psychological violence, as well as intimidation and cyber harassment...

Declaration of Berlin on Racism in Medicine

10.10.2022

Racism in all its forms exists in medicine throughout the world and has a direct impact on patients and their health, the World Medical Association said today. In a new Declaration adopted at its annual General Assembly in Berlin, the WMA acknowledges that racism is structural and deeply engrained in health care and that this is a public health threat.

The statement, entitled the Declaration of Berlin, says that physicians from marginalized communities face racism from patients, other physicians, and health professionals...

Physician’s Code of Medical Ethics updated

08.10.2022

The revised Code, regarded as the foundation of ethical principles for physicians worldwide, defines the professional duties of physicians towards their patients, other physicians and health professionals, themselves, and society as a whole. It was adopted today in a unanimous vote at the WMA’s annual General Assembly in Berlin by physician leaders from almost 60 national medical associations...

World Organisation for Animal Health (OIE) [to 15 Oct 2022]
WTO - World Trade Organisation [to 15 Oct 2022]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events [Selected]
Members discuss extending MC12 TRIPS Decision to COVID-19 diagnostics and therapeutics
13 October 2022
WTO members advanced discussions on whether to extend the TRIPS Decision adopted in June at the 12th WTO Ministerial Conference to COVID-19 diagnostics and therapeutics. At a meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) on 12-13 October, the chair of the Council, Ambassador Dr Lansana Gberie of Sierra Leone, urged delegations to submit text-based proposals indicating how they envisage an agreed outcome on this issue with a view to helping members reach a decision by the prescribed 17 December deadline.
[See Milestones above for detail]

WHO, WIPO, WTO to hold workshop on innovation and access to COVID-19 diagnostics
12 October 2022
The World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the WTO will hold on 28 October a joint virtual workshop on “Innovation and access to diagnostics for COVID-19 and beyond”. The event will be the third in the series of trilateral workshops which the Directors-General of the WHO, WIPO and the WTO have agreed to organize within the existing collaboration framework.

ARM [Alliance for Regenerative Medicine] [to 15 Oct 2022]
Selected Press Releases
The Alliance for Regenerative Medicine Announces Election of 2023 Officers, Executive Committee, and Board of Directors
October 11, 2022

BIO [to 15 Oct 2022]
Press Releases
Established Industry Leader Rachel King will Serve as BIO’s Interim Leader
October 11, 2022
The Biotechnology Innovation Organization (BIO) – the world’s largest science and public advocacy organization, representing 1,000 members — announced today that Rachel King, co-founder and former CEO of GlycoMimetics, Inc., has agreed to...

BIO Announces Leadership Update
October 10, 2022
Today, Dr. Michelle McMurry-Heath informed the Biotechnology Innovation Organization (BIO) Executive Committee that she is stepping down from her position as President and Chief Executive Officer effective October 11, 2022, and she has agreed to...

**DCVMN – Developing Country Vaccine Manufacturers Network**  [to 15 Oct 2022]
http://www.dcvmn.org/
News; Upcoming events
Panacea Biotec receives UNICEF & PAHO awards for supply of Pentavalent Vaccine (DTwP-HepB-Hib)

New Delhi, India, October 10, 2022: Panacea Biotec, one of India’s leading biotechnology companies, has received long-term supply awards worth US$ 127.30 million (around INR 1,040 Crore) from UNICEF and Pan American Health Organization (PAHO) for supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT® (DTwP-HepB-Hib).

UNICEF award is worth US$ 98.755 million (INR 813 Crore) for supply of 99.70 million doses during calendar years 2023-2027 and PAHO award is worth US$ 28.55 million (INR 235 Crore) for supply 24.83 million doses during calendar years 2023-2025...

**ICBA – International Council of Biotechnology Associations**  [to 15 Oct 2022]
https://internationalbiotech.org/news/
News
No new digest content identified.

**IFPMA**  [to 15 Oct 2022]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

**International Alliance of Patients’ Organizations – IAPO**  [to 15 Oct 2022]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

**International Generic and Biosimilar Medicines Association [IGBA]**
https://www.igbamedicines.org/
News
Press Releases
No new digest content identified.

**PhRMA**  [to 15 Oct 2022]
http://www.phrma.org/
Press Releases
Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases - No new digest announcements identified

Bharat Biotech
Press Releases - No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias - No new digest announcements identified

Biological E
News - No new digest announcements identified

BioNTech
Press Releases
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
13 October 2022

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
12 October 2022

CanSinoBIO
News - Website not responding at inquiry

CIGB
Latest News - No new digest announcements identified

Cinnagen
Recent News - Website not responding at inquiry

Clover Biopharmaceuticals - China
News - No new digest announcements identified

Curevac [Bayer Ag – Germany]
News - No new digest announcements identified

Gamaleya National Center
Latest News and Events - See Russia above.
GSK

*Press releases for media*

13 October 2022

**GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial**

Data showed overall vaccine efficacy against RSV-lower respiratory tract disease in adults aged 60 years and above.

10 October 2022

**US FDA approves BOOSTRIX for immunisation during pregnancy for the prevention of whooping cough in newborn infants**

The US FDA has approved Boostrix for immunisation during the third trimester of pregnancy to help prevent pertussis (whooping cough).

IMBCAMS, China

*Home* - Website not responding at inquiry

Janssen/JNJ

*Press Releases* - No new digest announcements identified

Medicago

*Media* - No new digest announcements identified

Merck

*News releases*

**Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine**

October 12, 2022

**Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines**

October 10, 2022

Moderna

*Press Releases*

12 October, 2022

**Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age**

12 October, 2022

**Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine**

Nanogen

*News* - No new digest announcements identified

Novartis

*News* - No new digest announcements identified
Novavax
Press Releases
Oct 13, 2022
Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains

Oct 12, 2022
Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants

Oct 10, 2022
Novavax and SK bioscience File a Post Approval Change Application in South Korea for Nuvaxovid™ COVID-19 Vaccine as a Booster in Adults Aged 18 and Older

Oct 10, 2022
Switzerland’s Federal Office of Public Health Recommends Novavax Nuvaxovid™ COVID-19 Vaccine as a Booster in Adults Aged 18 and Older

Pfizer
Recent Press Releases
10.13.2022
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

10.12.2022
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
Press Releases - No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP
News - No new digest announcements identified

Sinovac
Press Releases - No new digest announcements identified

SK Biosciences
Press Releases - No new digest announcements identified

Valneva
Press Releases
October 10, 2022
Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientific Conferences

Vector State Research Centre of Viralology and Biotechnology
Home - Website not responding [404 error]

WestVac Biopharma
Media - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]  
[No website identified]

* * * * *
* * * *

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 13, 2022 Issue 3
https://www.tandfonline.com/toc/uabr21/current  
[Reviewed earlier]

AMA Journal of Ethics
Volume 24, Number 10: E913-1027 Oct 2022
https://journalofethics.ama-assn.org/issue/health-care-waste

Health Care Waste
Most health care generated waste is not hazardous, but it is voluminous. Health care organizations have obligations to manage waste in ways that minimize environmental impact and express their status
as good citizens of their global, domestic, and regional communities. Resource-rich countries generate on average more than double the amount of hazardous waste per bed per day than resource-poor countries, and waste processing is concentrated in minoritized communities nearly everywhere. Segregating waste and reducing overall volume are key to curbing primary and secondary emissions that contaminate air and water. Decarbonization and moving the health care sector to net-zero emissions are key expressions of sincerity about motivating health equity.

**American Journal of Infection Control**  
October 2022 Volume 50 Issue 10 p1077-1192  
http://www.ajicjournal.org/current  
[Reviewed earlier]

**American Journal of Preventive Medicine**  
October 2022 Volume 63 Issue 4 p469-668  
https://www.ajpmonline.org/current  
[Reviewed earlier]

**American Journal of Public Health**  
October 2022 112(10)  
http://ajph.aphapublications.org/toc/ajph/current  
[Reviewed earlier]

**American Journal of Tropical Medicine and Hygiene**  
Volume 107 (2022): Issue 3_Suppl (Sep 2022)  
https://www.ajtmh.org/view/journals/tpmd/107/3_Suppl/tpmd.107.issue-3_Suppl.xml  
*Malaria Transmission Blocking Vaccines*  
[Reviewed earlier]

**Annals of Internal Medicine**  
September 2022 Volume 175, Issue 9  
http://annals.org/aim/issue  
[Reviewed earlier]

**Artificial Intelligence – An International Journal**  
Volume 311 October 2022  
[New issue; No digest content identified]

**BMC Cost Effectiveness and Resource Allocation**  
http://resource-allocation.biomedcentral.com/  
(Accessed 15 Oct 2022)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its resulting disease, coronavirus disease 2019 (COVID-19), has spread to millions of people worldwide. Preliminary data from organ tr...

Authors: Aziza A. Ajlan, Tariq Ali, Hassan Aleid, Khalid Almeshari, Edward DeVol, Morad Ahmed Alkaff, Layal Fajji, Ali Alali, Dani Halabi, Sahar Althuwaidi, Saad Alghamdi, Asad Ullah, Abdulrahman Alrajhi, Khalid Bzeizi, Reem Almaghrabi, Kris Ann Hervera Marquez...  
Citation: BMC Infectious Diseases 2022 22:786  
Content type: Research Published on: 13 October 2022

Regular vaccination against SARS-CoV-2 may be needed to maintain immunity in 'at-risk' populations, which include healthcare workers (HCWs). However, little is known about the proportion of HCWs who might be h...

Authors: Neyme Veli, Christopher A. Martin, Katherine Woolf, Joshua Nazareth, Daniel Pan, Amani Al-Oraibi, Rebecca F. Baggaley, Luke Bryant, Laura B. Nellums, Laura J. Gray, Kamlesh Khunti and Manish Pareek  
Citation: BMC Medicine 2022 20:386
Pregnancy during COVID-19: social contact patterns and vaccine coverage of pregnant women from CoMix in 19 European countries

Evidence and advice for pregnant women evolved during the COVID-19 pandemic. We studied social contact behaviour and vaccine uptake in pregnant women between March 2020 and September 2021 in 19 European countr... Authors: Kerry L. M. Wong, Amy Gimma, Enny S. Paixao, Christel Faes, Philippe Beutels, Niel Hens, Christopher I. Jarvis and W. John Edmunds

Citation: BMC Pregnancy and Childbirth 2022 22:757

Preponderance of vaccine-preventable diseases hotspots in northern Ghana: a spatial and space-time clustering analysis from 2010 to 2014

Vaccine-preventable diseases (VPDs) persist globally with a disproportionately high burden in Low and Middle-Income Countries (LMICs). Although this might be partly due to the failure to sustain vaccination co... Authors: Daniel Amoako-Sakyi, Dorcas Obiri-Yeboah, Anthony Ofosu, Kwadwo Asamoah Kusi, Kingsley Osei, Richard Adade, Ebenezer Aniakwaa-Bonsu, Reginald Quansah, John Arko-Mensah, Brodrick Yeboah Amoah, Godwin Kwakye-Nuako, Eric Yaw Frimpong, Mariama Combasseré-Cherif, Hidaya Mohammed, Boubacar Maiga, Julius Fobil...

Citation: BMC Public Health 2022 22:1899

Preponderance of vaccine-preventable diseases hotspots in northern Ghana: a spatial and space-time clustering analysis from 2010 to 2014

Vaccine-preventable diseases (VPDs) persist globally with a disproportionately high burden in Low and Middle-Income Countries (LMICs). Although this might be partly due to the failure to sustain vaccination co... Authors: Daniel Amoako-Sakyi, Dorcas Obiri-Yeboah, Anthony Ofosu, Kwadwo Asamoah Kusi, Kingsley Osei, Richard Adade, Ebenezer Aniakwaa-Bonsu, Reginald Quansah, John Arko-Mensah, Brodrick Yeboah Amoah, Godwin Kwakye-Nuako, Eric Yaw Frimpong, Mariama Combasseré-Cherif, Hidaya Mohammed, Boubacar Maiga, Julius Fobil...

Citation: BMC Public Health 2022 22:1899

Content type: Research Published on: 12 October 2022

Preponderance of vaccine-preventable diseases hotspots in northern Ghana: a spatial and space-time clustering analysis from 2010 to 2014

Vaccine-preventable diseases (VPDs) persist globally with a disproportionately high burden in Low and Middle-Income Countries (LMICs). Although this might be partly due to the failure to sustain vaccination co... Authors: Daniel Amoako-Sakyi, Dorcas Obiri-Yeboah, Anthony Ofosu, Kwadwo Asamoah Kusi, Kingsley Osei, Richard Adade, Ebenezer Aniakwaa-Bonsu, Reginald Quansah, John Arko-Mensah, Brodrick Yeboah Amoah, Godwin Kwakye-Nuako, Eric Yaw Frimpong, Mariama Combasseré-Cherif, Hidaya Mohammed, Boubacar Maiga, Julius Fobil...

Citation: BMC Public Health 2022 22:1899

Content type: Research Published on: 12 October 2022

BMJ Evidence-Based Medicine

October 2022 - Volume 27 - 5
The art and science of building castles in the sky and houses of cards that don’t collapse
Joseph L. Goldstein

The creative process in art and science involves two phases—generating and exploring new and wild ideas (building castles in the sky) and then narrowing down and focusing on the most tractable and useful ones (building houses of cards that don’t topple over).

Motherhood and vaccine refusal in the United Kingdom: A new examination of gender, identity and the journey to contemporary non-vaccination
Laura Sythes, Helen Bedford
Pages: 979-989
First Published: 24 January 2022
Editorial

**Off-label Use of Pharmaceutical Agents in Children: The Drumbeat Quickens**
Paul Beninger
Published online: August 23, 2022
p1173-1175

*Original Research*

Paul Beninger, et al.
Published online: July 24, 2022
p1225-1236
Open Access

**Clinical Trials**
Volume 19 Issue 5, October 2022
https://journals.sagepub.com/toc/ctja/19/5
[Reviewed earlier]

**Conflict and Health**
http://www.conflictandhealth.com/
[Accessed 15 Oct 2022]
[No new digest content identified]

**Contemporary Clinical Trials**
Volume 120 September 2022
https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/120/suppl/C
[Reviewed earlier]

**The CRISPR Journal**
Volume 5, Issue 4 / August 2022
https://www.liebertpub.com/toc/crispr/5/4
[Reviewed earlier]

**Current Genetic Medicine Reports**
Volume 10, issue 1, March 2022
https://link.springer.com/journal/40142/volumes-and-issues/10-1
[Reviewed earlier]

**Current Opinion in Infectious Diseases**
October 2022 - Volume 35 - Issue 5
Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 22, Issue 3  Pages: 123-180  September 2022
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 32, Issue 7, 2022
http://www.tandfonline.com/toc/cdip20/current
[New issue; No digest content identified]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 4 - August 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 46, Issue 4  Pages: 853-1126  October 2022
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 23  Issue 10  6 October 2022
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 28, Number 10—October 2022
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Epidemiology and Infection
Volume 150 - 2022
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 44, Issue 5  Pages: 1-21  September–October 2022
https://onlinelibrary.wiley.com/toc/25782363/current
Protecting healthy volunteers • IRBs and research biopsies
[Reviewed earlier]

Ethics & International Affairs
Spring 2022 (36.1) | March 10, 2022
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 24  October 2022
Review article  Full text access
Vaccine hesitancy, misinformation in the era of Covid-19: Lessons from the past
D. Orsini, R. Bianucci, F.M. Galassi, D. Lippi, M. Martini
Article 100812

The European Journal of Public Health
Volume 32, Issue 5, October 2022
https://academic.oup.com/eurpub/issue/32/5
[Reviewed earlier]

Expert Review of Vaccines
Vol 21 (9) 2022
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Foreign Affairs
Volume 101, Number 5  September/October 2022
https://www.foreignaffairs.com/issues/2022/101/5
[New issue; No relevant content identified]

**Forum for Development Studies**  
Volume 49, 2022 - Issue 2  
http://www.tandfonline.com/toc/sfds20/current  
[Reviewed earlier]

**Genetics in Medicines**  
[Reviewed earlier]

**Genome Medicine**  
https://genomemedicine.biomedcentral.com/articles  
[Accessed 15 Oct 2022]  
[No new digest content identified]

**Global Health Action**  
Volume 15, Issue 1 (2022)  
https://www.tandfonline.com/toc/zgha20/current?nav=tocList  
[Reviewed earlier]

**Global Health: Science and Practice (GHSP)**  
August 2022 | Volume 10 | Number 4  
http://www.ghspjournal.org/content/current  
[Reviewed earlier]

**Global Legal Monitor – Library of Congress/USA**  
https://www.loc.gov/collections/global-legal-monitor/  
[Accessed 15 Oct 2022]  
[No new digest content identified]

**Global Public Health**  
Volume 17, Issue 10 (2022)  
http://www.tandfonline.com/toc/rgph20/current  
*(Re)imagining Research, Activism, and Rights at the Intersections of Sexuality, Health, and Social Justice*  
[Reviewed earlier]

**Globalization and Health**
http://www.globalizationandhealth.com/
[Accessed 15 Oct 2022]
[No new digest content identified]

**Health and Human Rights**
Volume 24, Issue 1, June 2022
[Reviewed earlier]

**Health Economics, Policy and Law**
Volume 17 - Issue 4 - October 2022
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

**Health Policy and Planning**
Volume 37, Issue 8, October 2022
https://academic.oup.com/heapol/issue/37/8
[Reviewed earlier]

**Health Research Policy and Systems**
http://www.health-policy-systems.com/content
[Accessed 15 Oct 2022]
[No new digest content identified]

**Human Gene Therapy**
Volume 33, Issue 17-18 / September 2022
https://www.liebertpub.com/toc/hum/33/17-18
[Reviewed earlier]

**Humanitarian Practice Network**
https://odihpn.org/
*Featured Publications*
[No new digest content identified]

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)
Volume 18, Issue 5, 2022
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList
[Reviewed earlier]

**Immunity**
Vardhana and colleagues discuss how discrete immunological defects in individuals with cancer and other immunosuppressive conditions have informed our understanding of the role of the immune system in protection and toxicity from SARS-CoV-2. They discuss how these immune defects affect the protective impact of vaccination strategies in these individuals and provide insight to limit COVID-19-associated morbidity in this high-risk population.

The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination
Carina Saggau, et al.
Determinants of immune-response quality to SARS-CoV-2 remain poorly defined. Saggau et al. examine spike-specific naive and memory T cells pre- and post-vaccination and track pre-existing memory T cell receptors. They define T cell parameters of high-quality vaccine responses and identify high pre-existing memory and low naive T cell contributions as predictors of low-quality responses, particularly in the elderly.

Impact of the national hepatitis B immunization program in China: a modeling study
Authors: Zhixi Liu, Mengying Li, David W. Hutton, Abram L. Wagner, Ye Yao, Wenlong Zhu, Lingsheng Cao, Shenglan Tang, Jinhua Pan, Yesheng Wang, Qi Zhao, Hong Ren, Ying Wang and Weibing Wang
Content type: Research Article 11 October 2022
International Journal of Community Medicine and Public Health
Vol 9, No 10 (2022) October 2022
https://www.ijcmph.com/index.php/ijcmph/issue/view/92
[Reviewed earlier]

International Journal of Epidemiology
Volume 51, Issue 5, October 2022
https://academic.oup.com/ije/issue
COVID-19
Interplay between demographic, clinical and polygenic risk factors for severe COVID-19
Samantha S R Crossfield, Natalie J M Chaddock, Mark M Iles, Mar Pujades-Rodriguez, Ann W Morgan
International Journal of Epidemiology, Volume 51, Issue 5, October 2022, Pages 1384–1395,
https://doi.org/10.1093/ije/dyac137

International Journal of Human Rights in Healthcare
Volume 15 Issue 3, 2022
https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/3
Special Issue: Children, young people and their international human right to healthcare
[Reviewed earlier]

JAMA
October 11, 2022, Vol 328, No. 14, Pages 1381-1470
https://jamanetwork.com/journals/jama/currentissue
Original Investigation
Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2
Infection and Severe COVID-19 Outcomes
Dan-Yu Lin, PhD; Yu Gu, BS; Yangjian Chen Xu, BS; et al.
free access
This study uses data from March 2020 to June 2022 to examine the association of the primary and booster COVID-19 vaccines with SARS-CoV-2 infection, hospitalization, and death.

Editorial
Long-term Protection Associated With COVID-19 Vaccination and Prior Infection
Mark W. Tenforde, MD, PhD; Ruth Link-Gelles, PhD; Manish M. Patel, MD

Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2,
mRNA-1273, and Ad26.COV2.S Vaccines
J. Daniel Kelly, MD, PhD; Samuel Leonard, MS; Katherine J. Hoggatt, PhD; et al.
free access
This retrospective cohort study assesses incidence of breakthrough COVID-19 and hospitalization with COVID-19 pneumonia or death among adults who received a vaccination series plus 1 booster against SARS-CoV-2.

**Viewpoint**

Social Media and Medical Misinformation-Confronting New Variants of an Old Problem
Dhruv Khullar, MD, MPP
free access has audio

This Viewpoint describes several proposals to mitigate the role of social media in medical misinformation from the ABIM Foundation’s 2022 Forum, including algorithmic adjustment, misinformation research and surveillance, and medical professional training and community engagement.

**JAMA Pediatrics**

October 2022, Vol 176, No. 10, Pages 959-1055
[Reviewed earlier]

https://jamanetwork.com/journals/jamapediatrics/currentissue

**JBI Evidence Synthesis**

October 2022 - Volume 20 - Issue 10
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx

EDITORIAL
Partnerships needed to leverage evidence-based practice in African health care settings
Uhavenimana, Thierry Claudien

**Journal of Adolescent Health**

October 2022. Volume 71. Issue 4. p381-520
https://www.jahonline.org/current

**Priority Indicators for Adolescent Health Measurement – Recommendations From the Global Action for Measurement of Adolescent Health (GAMA) Advisory Group**

Andrew D. Marsh, et al.
Published online: June 29, 2022
p455-465
Open Access

**Journal of Artificial Intelligence Research**

Vol. 75 (2022)
https://www.jair.org/index.php/jair

Contents

Can We Automate Scientific Reviewing?
Weizhe Yuan, Pengfei Liu, Graham Neubig
Abstract
The rapid development of science and technology has been accompanied by an exponential growth in peer-reviewed scientific publications. At the same time, the review of each paper is a laborious process that must be carried out by subject matter experts. Thus, providing high-quality reviews of this growing number of papers is a significant challenge. In this work, we ask the question “can we automate scientific reviewing?”, discussing the possibility of using natural language processing (NLP) models to generate peer reviews for scientific papers. Because it is non-trivial to define what a “good” review is in the first place, we first discuss possible evaluation metrics that could be used to judge success in this task. We then focus on the machine learning domain and collect a dataset of papers in the domain, annotate them with different aspects of content covered in each review, and train targeted summarization models that take in papers as input and generate reviews as output. Comprehensive experimental results on the test set show that while system-generated reviews are comprehensive, touching upon more aspects of the paper than human-written reviews, the generated texts are less constructive and less factual than human-written reviews for all aspects except the explanation of the core ideas of the papers, which are largely factually correct. Given these results, we pose eight challenges in the pursuit of a good review generation system together with potential solutions, which, hopefully, will inspire more future research in this direction.

Journal of Community Health
Volume 47, issue 5, October 2022
[Reviewed earlier]

Journal of Development Economics
Volume 158  September 2022
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 4, October 2022
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
September 2022 - Volume 76 - 9
https://jech.bmj.com/content/76/9
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 15, Issue 3  Pages: 181-314  September 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]
Journal of Global Ethics
Volume 18, Issue 1, 2022
http://www.tandfonline.com/toc/rjge20/current

Special Issue: Relational Theory: Feminist Approaches, Implications, and Applications
Guest Editors Christine M. Koggel, Ami Harbin and Jennifer J. Llewellyn
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 33, Number 3, August 2022
https://muse.jhu.edu/issue/48370
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 24, issue 5, October 2022
Contents
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 20, 2022 Issue 3
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of Infectious Diseases
Volume 226, Issue 7, 1 October 2022
https://academic.oup.com/jid/issue/226/7
Review
In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis
Shelly Bolotin, Selma Osman, Stephanie L Hughes, Archchun Ariyarajah, Andrea C Tricco ...
The Journal of Infectious Diseases, Volume 226, Issue 7, 1 October 2022, Pages 1127–1139,
https://doi.org/10.1093/infdis/jiac039
This review assesses whether humoral immunity from measles vaccine or infection wanes over time. Antibody levels in individuals receiving 2 doses of MCV declined nonlinearly over the 20 years of available data but did not fall below the protective threshold.

Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses
Laila Sara Arroyo Mühr, Carina Eklund, Camilla Lagheden, Tiina Eriksson, Ville N Pimenoff ...
The Journal of Infectious Diseases, Volume 226, Issue 7, 1 October 2022, Pages 1195–1199,
https://doi.org/10.1093/infdis/jiac190
Comparison of antibody levels against human papillomavirus after vaccination found highest antibody levels against HPV16/18 after bivalent vaccination and against HPV6/11/31/33/45/52/58 after nonavalent vaccination. Antibodies against nonvaccine types were also found (HPV31/33/35/45 or 58 after bivalent; HPV35 after nonavalent vaccine).

Journal of International Development
Volume 34, Issue 7 Pages: 1257-1452 October 2022
https://onlinelibrary.wiley.com/toc/10991328/current

RESEARCH ARTICLES

Bringing about the data revolution in development: What data skills do aspiring development professionals need?
Rachel Bennett, Gianmarco Alberti, Aytekin Çibik, Tatiana Eremenko, Saviour Formosa, Janice Formosa-Pace, María Jiménez-Buedo, Kenneth Lynch, Leire Salazar, Paloma Ubeda
Pages: 1381-1397
First Published: 08 March 2022
Open Access

Journal of Medical Ethics
October 2022 - Volume 48 - 10
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 9, Issue 3 (2022)
https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
September 2022 Volume 248 p1-136
http://www.jpeds.com/current
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 15 Oct 2022]

Vaccination process evaluation at COVID-19 vaccination centers in Lebanon: a national study
Upon the authorization of COVID-19 vaccines worldwide, national and international standards were developed to help integrate mass COVID-19 immunization campaigns into the healthcare network. The primary object...
Authors: Abeer Zeitoun, Souheil Hallit, Maya Helali, Sirine Chehade, Carla Allam, Aya Ibrahim, Hani Dimassi and Rita Karam
Citation: Journal of Pharmaceutical Policy and Practice 2022 15:63
Journal of Public Health Management & Practice
September/October 2022 - Volume 28 - Issue 5
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 43, issue 2, June 2022
[Reviewed earlier]

Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
October 2022 Volume 19 Issue 195
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]

Journal of Travel Medicine
Volume 29, Issue 6, August 2022
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology
Volume 96 Number 18 September 2022
http://jvi.asm.org/content/current
[Reviewed earlier]

The Lancet
Oct 15, 2022 Volume 400 Number 10360 p1281-1380, e10
https://www.thelancet.com/journals/lancet/issue/current
Comment
Prioritisation of COVID-19 boosters in the omicron era
Stephanie A Irving, Maria E Sundaram

The scientific communication ecosystem: the responsibility of investigators
Howard Bauchner, Frederick P Rivara
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales

Utkarsh Agrawal, et al.

Summary

Background

Current UK vaccination policy is to offer future COVID-19 booster doses to individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups of the population could benefit most. In response to an urgent request from the UK Joint Committee on Vaccination and Immunisation, we aimed to identify risk factors for severe COVID-19 outcomes (ie, COVID-19-related hospitalisation or death) in individuals who had completed their primary COVID-19 vaccination schedule and had received the first booster vaccine.

Methods

We constructed prospective cohorts across all four UK nations through linkages of primary care, RT-PCR testing, vaccination, hospitalisation, and mortality data on 30 million people. We included individuals who received primary vaccine doses of BNT162b2 (tozinameran; Pfizer–BioNTech) or ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccines in our initial analyses. We then restricted analyses to those given a BNT162b2 or mRNA-1273 (elasomeran; Moderna) booster and had a severe COVID-19 outcome between Dec 20, 2021, and Feb 28, 2022 (when the omicron (B.1.1.529) variant was dominant). We fitted time-dependent Poisson regression models and calculated adjusted rate ratios (aRRs) and 95% CIs for the associations between risk factors and COVID-19-related hospitalisation or death. We adjusted for a range of potential covariates, including age, sex, comorbidities, and previous SARS-CoV-2 infection. Stratified analyses were conducted by vaccine type. We then did pooled analyses across UK nations using fixed-effect meta-analyses.

Findings

Between Dec 8, 2020, and Feb 28, 2022, 16 208 600 individuals completed their primary vaccine schedule and 13 836 390 individuals received a booster dose. Between Dec 20, 2021, and Feb 28, 2022, 59 510 (0·4%) of the primary vaccine group and 26 100 (0·2%) of those who received their booster had severe COVID-19 outcomes. The risk of severe COVID-19 outcomes reduced after receiving the booster (rate change: 8·8 events per 1000 person-years to 7·6 events per 1000 person-years). Older adults (≥80 years vs 18–49 years; aRR 3·60 [95% CI 3·45–3·75]), those with comorbidities (≥5 comorbidities vs none; 9·51 [9·07–9·97]), being male (male vs female; 1·23 [1·20–1·26]), and those with certain underlying health conditions—in particular, individuals receiving immunosuppressants (yes vs no; 5·80 [5·53–6·09])—and those with chronic kidney disease (stage 5 vs no; 3·71 [2·90–4·74]) remained at high risk despite the initial booster. Individuals with a history of COVID-19 infection were at reduced risk (infected ≥9 months before booster dose vs no previous infection; aRR 0·41 [95% CI 0·29–0·58]).

Interpretation

Older people, those with multimorbidity, and those with specific underlying health conditions remain at increased risk of COVID-19 hospitalisation and death after the initial vaccine booster and should, therefore, be prioritised for additional boosters, including novel optimised versions, and the increasing array of COVID-19 therapeutics.

Funding

National Core Studies–Immunity, UK Research and Innovation (Medical Research Council), Health Data Research UK, the Scottish Government, and the University of Edinburgh.
The Lancet Child & Adolescent Health
Oct 2022 Volume 6 Number 10 p667-746
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health
Oct 2022 Volume 4 Number 10 e698-e764
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

Lancet Global Health
Oct 2022 Volume 10 Number 1 e1360-e1533
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

Lancet Infectious Diseases
Oct 2022 Volume 22 Number 10 p1399-1512, e279-e309
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
Oct 2022 Volume 7 Number 10 e801-e884
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
Oct 2022 Volume 10 Number 10 p925-1008, e87-e93
https://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]

Maternal and Child Health Journal
Volume 26, issue 10, October 2022
https://link.springer.com/journal/10995/volumes-and-issues/26-10
[New issue; No digest content identified]

Medical Decision Making (MDM)
Volume 42 Issue 7, October 2022
http://mdm.sagepub.com/content/current
[Reviewed earlier]
Studies linking diet with health must get a whole lot better

A research-rating system has identified gaps in studies that assess the connection between diet and various health risks.

A big chance for science at the heart of global policymaking

The new president of the United Nations General Assembly, Csaba Kőrösi, last month opened the body’s 77th session with a speech that signalled that science might come to play a more prominent part in the UN’s policymaking organ, at least during his tenure. Together with an earlier and more substantive move by the UN’s top diplomat, secretary-general António Guterres, this is a welcome chance for more research-informed policymaking.
Nature Medicine
Volume 28 Issue 10, October 2022
https://www.nature.com/nm/volumes/28/issues/10

Editorial 10 Oct 2022
Assessing the evidence of risk
In this issue, Nature Medicine presents the Burden of Proof studies led by the Institute for Health Metrics and Evaluation, which quantitatively evaluate the strength of evidence of risk–outcome relationships to better inform effective clinical and policy recommendations.

Perspective 10 Oct 2022
The Global Burden of Disease Study at 30 years
This Perspective reflects on the past, present and future of the dynamic, expanding public health endeavor that is the Global Burden of Disease Study.
Christopher J. L. Murray

Review Article 03 Oct 2022
How COVID-19 shaped mental health: from infection to pandemic effects
This Review discusses the impact of COVID-19 on mental health, from pandemic-related societal effects to direct infection-related neuropsychiatric sequelae, highlighting the lessons learned and outstanding knowledge gaps.
Brenda W. J. H. Penninx, Michael E. Benros, Christiaan H. Vinkers

Article 10 Oct 2022
The Burden of Proof studies: assessing the evidence of risk
A new Burden of Proof meta-analytic method that accounts for between-study heterogeneity and corrects for bias between different study designs is used to interpret the strength of evidence between different pairs of risk factors and health outcomes.
Peng Zheng, Ashkan Afshin, Christopher J. L. Murray

Nature Reviews Drug Discovery
Volume 21 Issue 10, October 2022
https://www.nature.com/nrd/volumes/21/issues/10
[Reviewed earlier]

Nature Reviews Genetics
Volume 23 Issue 10, October 2022
https://www.nature.com/nrg/volumes/23/issues/10
[Reviewed earlier]

Nature Reviews Immunology
Volume 22 Issue 10, October 2022
https://www.nature.com/nri/volumes/22/issues/10
[Reviewed earlier]
New Federal Incentives for Diversity in Clinical Trials
T.J. Hwang and O.W. Brawley

Perspective Roundtable: Diversity in Clinical Trials — Next Steps
C.J. Rosen, N.L. Cook, and C.H. Wilkins

njp Vaccines
https://www.nature.com/npjvaccines/
[Accessed 15 Oct 2022]
[No new digest content identified]

Pediatrics
Volume 150, Issue 4 October 2022
https://publications.aap.org/pediatrics/issue/150/3
[Reviewed earlier]

PharmacoEconomics
Volume 40, issue 10, October 2022
https://link.springer.com/journal/40273/volumes-and-issues/40-10
[New issue; No digest content identified]

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed 15 Oct 2022)
[No new digest content identified]

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 15 Oct 2022)
New rules for genomics-informed COVID-19 responses—Lessons learned from the first waves of the Omicron variant in Australia
Ashleigh F. Porter, Narelle Sherry, Patiyan Andersson, Sandra A. Johnson, Sebastian Duchene, Benjamin P. Howden
Opinion Piece | published 13 Oct 2022 PLOS Genetics
https://doi.org/10.1371/journal.pgen.1010415

PLoS Medicine
http://www.plosmedicine.org/  
(Accessed 15 Oct 2022)  
[No new digest content identified]

**PLoS Neglected Tropical Diseases**
http://www.plosntds.org/

**The dual burden of animal and human zoonoses: A systematic review**
Liz P. Noguera Z., Duriya Charypkhan, Sonja Hartnack, Paul R. Torgerson, Simon R. Rüegg
Research Article | published 14 Oct 2022 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0010540

**Communication in Neglected Tropical Diseases’ elimination: A scoping review and call for action**
Claudia Nieto-Sanchez, David M. Hatley II, Mario J. Grijalva, Koen Peeters Grietens, Benjamin R. Bates
Research Article | published 13 Oct 2022 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0009774

**Constructing, validating, and updating machine learning models to predict survival in children with Ebola Virus Disease**
Alicia E. Genisca, Kelsey Butler, Monique Gainey, Tzu-Chun Chu, Lawrence Huang, Eta N. Mbong, Stephen B. Kennedy, Razia Laghari, Fiston Nganga, Rigobert F. Muhayangabo, Himanshu Vaishnav, Shiromi M. Perera, Moyinoluwa Adeniji, Adam C. Levine, Ian C. Michelow, Andrés Colubri
Research Article | published 12 Oct 2022 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0010789

**PLoS One**
http://www.plosone.org/  
[Accessed 15 Oct 2022]

**The influence of place on COVID-19 vaccine coverage in Alberta: A multilevel analysis**
Yuba Raj Paudel, Crystal Du, Shannon Elizabeth MacDonald
Research Article | published 14 Oct 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0276160

**Winners and losers from Pfizer and Biontech’s vaccine announcement: Evidence from S&P 500 (Sub)sector indices**
Burcu Kapar, Steven Buigut, Faisal Rana
Research Article | published 14 Oct 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0275773

**Risk perception and subsidy policy-based voluntary vaccination driven by multiple information sources**
Bing Wang, Lili Wu, Xiao Hong, Yuexing Han
Research Article | published 13 Oct 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0276177
The impact of COVID-19 on implementation of mass testing, treatment and tracking of malaria in rural communities in Ghana: A qualitative study
Research Article | published 13 Oct 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0275976

Real-world effectiveness of pneumococcal vaccination in older adults: Cohort study using the UK Clinical Practice Research Datalink
Adam J. Streeter, Lauren R. Rodgers, Jane Masoli, Nan X. Lin, Alessandro Blé, Willie Hamilton, William E. Henley
Research Article | published 13 Oct 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0275642

Facebook as a source of access to medicines
Tomasz Zaprutko, Dorota Kopciuch, Anna Paczkowska, Józefina Sprawka, Julia Cynar, Monika Pogodzińska, Katarzyna Niewczas, Aleksandra Stolecka, Maria Sygit, Michał Michalak, Piotr Ratajczak, Krzysztof Kus
Research Article | published 13 Oct 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0275272

Relationship of spirituality, health engagement, health belief and attitudes toward acceptance and willingness to pay for a COVID-19 vaccine
Sri Handayani, Yohanes Andy Rias, Maria Dyah Kurniasari, Ratna Agustin, Yafi Sabila Rosyad, Ya Wen Shih, Ching Wen Chang, Hsiu Ting Tsai
Research Article | published 12 Oct 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0274972

Psychological and behavioral responses to the declaration of COVID-19 as a pandemic: A comparative study of Hong Kong, Singapore, and the U.S.
Jingshi (Joyce) Liu, Anirban Mukhopadhyay, Catherine Wing-Man Yeung
Research Article | published 10 Oct 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0275854

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 15 Oct 2022]

An introduction to the Marburg virus vaccine consortium, MARVAC
Brief Report  October 3, 2022
Sociocultural determinants of global mask-wearing behavior
Behavioral responses influence the trajectories of epidemics. During the COVID-19 pandemic, nonpharmaceutical interventions (NPIs) reduced pathogen transmission and mortality worldwide. However, despite the global pandemic threat, there was substantial ...
Luojun Yang, Sara M. Constantino, [...] Vítor V. Vasconcelos

Research Article  October 4, 2022
Masks as a moral symbol: Masks reduce wearers’ deviant behavior in China during COVID-19
Since the outbreak of COVID-19, mask wearing has become a global phenomenon. How do masks influence wearers’ behavior in everyday life? We examine the effect of masks on wearers’ deviant behavior in China, where mask wearing is mostly a public-health ...
Jackson G. Lu, Lesley Luyang Song, [...] Laura Changlan Wang

Research Article  October 4, 2022
Nobel and novice: Author prominence affects peer review
Peer review is a well-established cornerstone of the scientific process, yet it is not immune to biases like status bias, which we explore in this paper. Merton described this bias as prominent researchers getting disproportionately great credit for their ...
Jürgen Huber, Sabiou Inoua, [...] Vernon L. Smith

Prehospital & Disaster Medicine
Volume 37 - Issue 5 - October 2022
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 162  September 2022
[Reviewed earlier]

Proceedings of the Royal Society B
12 October 2022  Volume 289  Issue 1984
https://royalsocietypublishing.org/toc/rspb/current
[Reviewed earlier]
Free

Research funders, professional associations, and scientific journals have increasingly endorsed positions and established policies that recognize data as a public good (1). In the health research context, the promise of data sharing is to accelerate health research across borders and improve patient care (2). But this raises ethical concerns for research participants, researchers, and marginalized communities, such as questions about data ownership, risk of reidentification (for example, genomic datasets), data security, and appropriate consent processes (1). Data sharing also raises distinctive ethical challenges for community-engaged research (CEnR), a term encompassing diverse research collaborations with communities, from community consultation to community-based participatory research. We discuss key rationales and goals of data sharing in health research and of CEnR and highlight three areas of potential tension between these two movements: incentives and
benefit sharing; group harm and power structures; and researcher engagement and responsibility sharing...

Science and Engineering Ethics  
Volume 28, issue 5, October 2022  

[Reviewed earlier]

Science Translational Medicine  
Volume 14| Issue 666| 12 Oct 2022  
https://www.science.org/toc/stm/current

Editorial  
Leveraging technology to address current and future world issues  
BY Ralph Weissleder  
12 Oct 2022  
FULL ACCESS  
Biotechnology is essential to advance modern medicine and alleviate global health crises, yet commercialization is often wrought by competing forces.

Reviews  
Translating diagnostics and drug delivery technologies to low-resource settings  
BY Erin M. Euliano et al.  
12 Oct 2022  
Free  
Technologies for low-resource settings must prioritize accessibility and affordability to maximize their likelihood of clinical translation.

Social Science & Medicine  
Volume 308  September 2022  

[Reviewed earlier]

Systematic Reviews  
https://systematicreviewsjournal.biomedcentral.com/articles

[Accessed 15 Oct 2022]  
COVID-19 prevalence and infection control measures at homeless shelters and hostels in high-income countries: a scoping review  
The COVID-19 pandemic has disproportionately impacted homeless populations and service workers, especially within homeless shelter/hostel settings. To date, there have been few evidence syntheses examining out...  
Authors: Justine Levesque, Jordan Babando, Nathaniel Loranger, Shantel Johnson and David Pugh  
Citation: Systematic Reviews 2022 11:223  
Content type: Research Published on: 15 October 2022
Theoretical Medicine and Bioethics
Volume 43, issue 2-3, June 2022
[Reviewed earlier]

Travel Medicine and Infectious Diseases
Volume 49 September–October 2022
[Reviewed earlier]

Tropical Medicine & International Health
Volume 27, Issue 10 Pages: i-iv, 841-940 October 2022
https://onlinelibrary.wiley.com/toc/13653156/current
Reviews Free Access
**Pneumococcal vaccination coverage and willingness in mainland China**
Wei Hao Shao, Xiaorui Chen, Caifang Zheng, Gaili Wang, Bowen Zhang, Weidong Zhang
Pages: 864-872
First Published: 09 August 2022
Open Access

**RESEARCH ARTICLES**
**Boosting ethics review capacity in public health emergency situations: Co-creation of a training model for French-speaking research ethics committees**
Vivi Maketa, Flory Luzolo, Hypolite Muhindo Mavoko, Yves Claeyts, Felicien Munday, Robert Yemesi Benge, Willy Bongo Pasi, Darius Mankindu, Samuel Mampunza, Philippe Lukanyu, Muteho Kasongo, Edmond Ntabe Namegabe, Leopold Kambale Karafuli, Delphin Phanzu Mavinga, Emmanuel Milandu Massamba, César-Augustin Muaka Khoso, Raffaella Ravinetto
Pages: 934-940
First Published: 21 August 2022

Vaccine
Volume 40, Issue 41 Pages 5843-6000 (29 September 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/41
Discussion Full text access
**Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021—March 2022**
Holly J. Prudden, Sharon L. Achilles, Celina Schocken, Nathalie Broutet, ... Sami L Gottlieb
Pages 5843-5855

Short communication Full text access
**COVID-19 vaccine confidence and reasons for vaccination among health care workers and household members**
Angela K. Ulrich, Grace K. Pankratz, Bruno Bohn, Stephanie Yendell, ... Ryan T. Demmer
Review article  Abstract only
Modern biotechnological strategies for vaccine development in aquaculture – Prospects and challenges
T.A. Jose Priya, Sudha Kappalli
Pages 5873-5881

Research article  Open access
Travelers and travel vaccines at six health care systems in the Vaccine Safety Datalink
Bruno Lewin, Lei Qian, Runxin Huang, Lina S. Sy, ... Steven J. Jacobsen
Pages 5904-5911

Research article  Full text access
Educational videos to address vaccine hesitancy in childhood immunization
Teti Adriana Lubis, Hartono Gunardi, Herqutanto, Soedjatmiko Soedjatmiko, ... Aman Bhakti Pulungan
Pages 5965-5970

Value in Health
October 2022 Volume 25 Issue 10 p1663-1804
https://www.valueinhealthjournal.com/current
[Reviewed earlier]

:::::::
:::::::

Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles
Selected Research
No new digest content identified.

medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...
[Filter: All articles]
Selected Research
Monkeypox vaccination willingness, determinants, and communication needs in gay, bisexual, and other men who have sex with men, in the context of limited vaccine availability in the Netherlands (Dutch MPX-survey)
Perceptions and predictors of COVID-19 vaccine hesitancy among health care providers across five countries in sub-Saharan Africa
Isabel Madzorera, Livesy Naafoe Abokyi, Edward Apraku, Temesgen Azemraw, Valentin Boudo, Christabel James, Dongqing Wang, Frank Mapendo, Ourohiré Millogo, Nega Assefa, Angela Chukwu, Firehiwot Workneh, Bruno Lankoande, Elena C. Hemler, Abbas Ismail, Sulemana Abubakari, Kwaku Poku Asante, Yemane Berhan, Japhet Killewo, Ayoade Oduola, Ali Sie, Abdramane Soura, Mary Mwanyika-Sando, Said Vual, Emily Smith, Till Baernighausen, Raji Tajudeen, Wafaie W Fawzi
medRxiv 2022.10.11.22280952; doi: https://doi.org/10.1101/2022.10.11.22280952

Open Research: Examples of good practice, and resources across disciplines
Emily K. Farran
Priya Silverstein
Aminath A. Ameen
Iliana Misheva
Camilla Gilmore
Last edited: Oct 14, 2022 UTC
Engineering Arts and Humanities Business Architecture Physical Sciences and Mathematics Medicine and Health Sciences Life Sciences Education Law Social and Behavioral Sciences
Open research is best described as “an umbrella term used to refer to the concepts of openness, transparency, rigor, reproducibility, replicability, and accumulation of knowledge” (Crüwell et al., 2019, p. 3). Although a lot of open research practices have commonly been discussed under the term “ope... OSF Preprints

Covid-19 effects on medical industry
Tan Kian Hua
Last edited: Oct 10, 2022 UTC
The COVID-19 pandemic has had a significant influence on the medical system and pharmaceutical sector in practically every nation on the planet. Communication with patients in their homes away from clinics was a typical practice in order to give safety actions to the healthcare team; however, health ...
Report

R&D for the public good: Ways to strengthen societal innovation in the United States
Darrell M. West
Monday, October 10, 2022

Center for Global Development   [to 15 Oct 2022]
https://www.cgdev.org/
All Research [Selected]
No new digest content identified

Chatham House   [to 15 Oct 2022]
https://www.chathamhouse.org/
Selected Analysis, Comment
No new digest content identified

CSIS   [to 15 Oct 2022]
https://www.csis.org/
Selected Reports
No new digest content identified.

Kaiser Family Foundation   [to 15 Oct 2022]
https://www.kff.org/search/?post_type=press-release
Press Releases
No new digest content identified.

ODI [Overseas Development Institute]   [to 15 Oct 2022]
Publications
No new digest content identified.

Pew Research Center   [to 15 Oct 2022]
https://www.pewresearch.org/
Latest Publications
Short Read | Oct 11, 2022
For many U.S. moms, pandemic brought increase in time spent caring for kids while doing other things
  Widespread child care challenges from the coronavirus pandemic lasted into 2021 for some U.S. parents

Rand   [to 15 Oct 2022]
https://www.rand.org/pubs.html
Reports, Selected Journal Articles
No new digest content identified.

Urban Institute  [to 15 Oct 2022]
https://www.urban.org/publications
New Research Publications

World Economic Forum  [to 15 Oct 2022]
https://www.weforum.org/press/
Media
No new digest content identified.

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).
Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.